<DOC>
	<DOCNO>NCT01427257</DOCNO>
	<brief_summary>Primary objective : To compare pharmacokinetic profile PB1023 single dose administer subcutaneous injection two formulation ( concentration ) . Secondary objective : To evaluate safety tolerability two formulation PB1023 Injection administer subcutaneous injection adult subject T2DM . To evaluate impact pharmacokinetic profile PB1023 single 90 mg dose formulation B ( 100 mg/mL ) administer cold 2 8°C subcutaneous injection .</brief_summary>
	<brief_title>Pharmacokinetic Profile Two Formulations PB1023 Following Single Subcutaneous Injection Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Willing able sign write informed consent follow study relate procedure . Males post menopausal surgically sterile female age 18 75 year age inclusive . Diagnosed T2DM ≥ 6 month . HbA1c ≥ 6.0 % diet exercise control , ≥5.8 % take one glucose lower agent Weight ≥ 45 kg BMI ≤ 40 kg/m2 In otherwise stable health except T2DM ( clinically significant laboratory abnormality , vital sign , ECG find clinically significant underlying disease would put subject risk participation study ) . Receiving stable dos concomitant medication 30 day prior dose . Criteria Participation Period 3 : Received PB1023 Injection 50 mg/mL 100 mg/mL Period 1 2 study adequate pharmacokinetic sample collect evaluation pharmacokinetic profile . Currently take Byetta® Victoza® . Previously receive PB1023 Injection study protocol . Known allergy serious adverse effect approve investigational GLP1 receptor analog/agonist . Unstable cardiovascular disease define : History stroke , transient ischemic attack , myocardial infarction within 6 month prior Screening visit . Screening ( duplicate supine reading ) BP ≥ 160 mmHg ( systolic ) ≥ 100 mmHg ( diastolic ) . Mean triplicate 12lead ECG demonstrate QT interval ( correct ) ( QTc ) &gt; 450 msec male &gt; 470 msec female Screening visit , history evidence long QT syndrome . Based contraindications/warnings identify GLP1 receptor agonist , subject exclude : History , symptom sign pancreatitis severe gastrointestinal disease ( i.e. , gastroparesis ) Personal family history medullary thyroid tumor history Multiple Endocrine Neoplasia Syndrome Type 2 . Note : Abnormal serum calcitonin screen exclude subject participation . Clinically significant renal and/or hepatic dysfunction screen indicate follow : eGFR calculate MDRD &lt; 60 mL/min Urine dipstick protein &gt; 2+ ( 100 mg/dL ) urine protein 2+ Urine Protein/Creatinine ratio &gt; 1.0 ( &gt; 1000 mg/g ) Alanine aminotransferase ( ALT ) &gt; 2 x ULN Aspartate aminotransferase ( AST ) &gt; 2 x ULN Serum bilirubin ≥ 1.6 mg/dL Pregnant lactating female Known history active alcohol drug abuse within 12 month prior Screening positive alcohol and/or drug screen . Positive Human Immunodeficiency Virus ( HIV ) antibody , Hepatitis B surface antigen ( HBsAg ) Hepatitis C Virus ( HCV ) antibody . Participating study receive investigational drug device within 30 day prior Screening visit take part nondrug study opinion Investigator would interfere outcome study . Other medical ( i.e. , acute chronic illness ) psychiatric condition opinion Investigator would place subject increase risk , confound primary study endpoint , would preclude obtain voluntary consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>